The test also concluded that an addition of 10-20% of ProGO to un-hydrolysed whey protein isolates (WPI), showed a significant increase in the rate of nitrogen absorption versus un-hydrolysed WPI alone.
Currently, hydrolysed and un-hydrolysed whey proteins are the most common sources to improve muscle recovery applied in human sport nutrition.
- The results clearly indicate the superiority of Hofseth BioCares marine based proteins compared to traditional whey-based proteins, and Hofseth BioCare is geared to take advantage of these results to expand its market shares and achieve premium prices for its products, says CEO Sjur Jenssen in Hofseth BioCare.
INAF is a Research Institute of the Laval University in Quebec, Canada. INAF focus on the understanding of relationships between foods, food components, nutrition and health. INAF puts science at the service of nutrition to ensure its actions lead to concrete and durable results that benefit the population's health and the bio-food sector.
In June 2012, Hofseth BioCare signed an exclusive agreement with US-based Roxlor for the distribution of ProGO to the North American human nutrition market. Roxlor will present the results from the INAF-study at the Natural Expo Show in Anaheim California on the 8-10 March.
For more information please contact:
Sjur Jenssen, CEO Hofseth BioCare ASA
Tel: +47 9155 3514
Email: sj@h-bc.no
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biomarine company with the key objective to provide high value added biomarine ingredients for human applications. The Company is founded on the core value of sustainability and optimal use of natural resources. Through innovative production technology and logistics, Hofseth BioCare is able to preserve the quality of protein, calcium and oil extracted from fish off-cuts. Products that previously could only be used as animal feed can now be made suitable for human consumption. HBCs objective is thus to contribute to efficient use of marine resources and entering the higher profit market of quality ingredients for human applications.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.